Best Peptides for Anxiety and Stress: Selank, Semax, DSIP, and More

Anxiety disorders are the most common mental health condition worldwide, affecting an estimated 284 million people. Yet the pharmaceutical landscape for anxiety remains dominated by medications with significant side effects, dependency risk, or limited efficacy for many patients — benzodiazepines, SSRIs, SNRIs, and buspirone each carry meaningful drawbacks.

Peptides offer a different approach: several compounds developed primarily in Russia and Eastern Europe act directly on anxiety-related neurological pathways with remarkable evidence of anxiolytic and adaptogenic effects. This guide covers the five best-supported peptides for anxiety and stress, their mechanisms, and what the research shows.

Understanding Anxiety at the Neurochemical Level

Anxiety involves dysregulation across several neurochemical systems:

• GABA deficiency or receptor hyposensitivity: GABA is the primary inhibitory neurotransmitter; most acute anti-anxiety drugs (benzos) enhance GABA activity
• Serotonin dysregulation: Low serotonin signaling is implicated in generalized anxiety and social anxiety
• HPA axis overactivation: Chronic stress drives excessive cortisol, which reshapes the brain's threat-detection circuitry over time
• BDNF deficiency: Brain-derived neurotrophic factor supports hippocampal neuroplasticity; low BDNF is associated with anxiety and depression
• Neuroinflammation: Elevated inflammatory cytokines (TNF-alpha, IL-6, IL-1) directly affect mood and anxiety through central pathways

The peptides below address these mechanisms through targeted, often multi-pathway actions.

Selank: The Tuftsin-Based Anxiolytic

Selank is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a stabilized analog of tuftsin, a naturally occurring tetrapeptide derived from IgG antibodies that plays roles in both immune modulation and CNS signaling.

Mechanism of Action

Selank's anxiolytic effects appear to operate through several converging pathways:

GABA modulation: Selank enhances GABAergic neurotransmission — similar in principle to benzodiazepines, but without binding to benzodiazepine receptors directly, and without the dependence, sedation, or cognitive impairment associated with benzo use.

BDNF upregulation: Selank increases expression of BDNF in the hippocampus and prefrontal cortex, promoting neuroplasticity and resilience. This is one of the mechanisms by which chronic selank use appears to produce lasting anxiety reduction rather than just acute symptom management.

Serotonin and dopamine modulation: Studies show selank normalizes serotonin turnover in stressed animals, and has dopaminergic effects that may contribute to improved motivation and reduced anhedonia alongside its anxiolytic effects.

Enkephalin metabolism: Selank inhibits enkephalin-degrading enzymes, increasing levels of endogenous opioid peptides that modulate pain and stress responses.

Research Evidence

Selank has been studied in over 20 clinical and preclinical trials. Russian clinical studies show it reduces anxiety scores comparably to benzodiazepines (specifically phenazepam and grandaxin) in generalized anxiety disorder without sedation, cognitive impairment, or withdrawal. It also improved cognitive performance in anxious patients — an effect benzodiazepines conspicuously lack.

A 2008 study in patients with generalized anxiety disorder found selank reduced anxiety scores by approximately 50%, with notable improvements in memory and attention. Its immune-modulating effects (via tuftsin mechanisms) may also reduce neuroinflammation that contributes to anxiety.

Dosing

Intranasal: 250–500 mcg per nostril, 2–3 times daily. Intranasal delivery provides rapid CNS access. Subcutaneous injection at similar doses is also used. Daily use for 2–4 weeks is typical, followed by assessment. Selank does not appear to cause dependence.

Semax: Cognitive Enhancement and Stress Resilience

Semax is a synthetic heptapeptide derived from ACTH (adrenocorticotropic hormone) — specifically a fragment that retains neuroprotective and nootropic properties without the adrenal-stimulating effects of full ACTH. It was developed in Russia and is approved as a nasal spray there for stroke, TBI, and cognitive conditions.

For a deep dive on nootropic peptides, see the semax and selank peptide guide.

Mechanism of Action

BDNF and NGF upregulation: Semax dramatically increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) — sometimes by 3–8x in animal studies. This drives neuroplasticity, supports hippocampal function, and builds long-term resilience against stress and anxiety.

Serotonin and dopamine system enhancement: Semax modulates both serotonin and dopamine receptor density and turnover, with effects that appear to normalize rather than simply increase these systems.

Anti-neuroinflammatory effects: Semax reduces the expression of inflammatory cytokines in the CNS, including TNF-alpha and IL-1, which directly impact anxiety and mood through neuroinflammatory pathways.

HPA axis modulation: Unlike full ACTH, semax modulates the stress response without triggering the cortisol cascade — producing stress adaptogenicity rather than stress amplification.

Research Evidence

Animal studies consistently show semax reduces anxiety behaviors in open-field, elevated plus-maze, and forced swim tests. Human clinical studies in Russia document cognitive improvement, reduced anxiety, and improved stress tolerance in both clinical and healthy populations. Post-stroke patients show cognitive improvements that extend to mood and anxiety reduction.

Dosing

Intranasal: 100–300 mcg per nostril, 1–2 times daily. Effects are often noticeable within the first few days. 2–4 week cycles with breaks are common. Semax tends to be energizing rather than sedating, so morning or midday dosing is preferred for most users.

DSIP: Delta Sleep Inducing Peptide

DSIP (delta sleep inducing peptide) is a nonapeptide that — as its name implies — was first identified for its ability to induce slow-wave sleep in animals. Its relevance to anxiety extends from the well-established bidirectional relationship between sleep quality and anxiety.

Mechanism of Action

DSIP promotes delta (slow-wave) sleep, the most restorative phase of sleep and the primary window for cortisol regulation, memory consolidation, and neurological repair. Beyond sleep, DSIP also:

• Modulates the HPA axis: DSIP reduces corticotropin-releasing factor (CRF) activity, blunting the stress response at the hypothalamic level
• Antioxidant effects: DSIP reduces oxidative stress in the brain, a known contributor to neurological anxiety
• Normalizes circadian disruption: Many anxiety disorders involve dysregulated circadian rhythms; DSIP helps restore normal sleep-wake architecture

Research Evidence

Studies in insomnia and chronic pain patients show DSIP significantly improves sleep architecture, with cascading improvements in stress resilience and daytime anxiety. The relationship between DSIP and anxiety is partly mediated through sleep improvement — reducing the sleep deprivation that chronically drives anxiety dysregulation.

DSIP also shows analgesic properties and may reduce the anxiety associated with chronic pain conditions.

Dosing

100–500 mcg subcutaneously before bed. DSIP is typically used in cycles of 1–2 weeks for sleep and anxiety applications. It is one of the gentler peptides in this space and can be useful when sleep disruption is a primary driver of anxiety.

BPC-157: The Gut-Brain Axis

BPC-157 is primarily known for tissue repair, but its effects on the gut-brain axis and monoamine neurotransmitter systems make it meaningfully relevant for anxiety.

Mechanism for Anxiety

Dopamine and serotonin modulation: BPC-157 modulates the dopamine and serotonin systems in the brain. Animal studies show it protects against dopamine depletion in stress models and normalizes dopaminergic neurotransmission.

Gut-brain axis: An estimated 90% of serotonin is produced in the gut, and the gut microbiome communicates bidirectionally with the brain through the vagus nerve. BPC-157's ability to heal gut mucosa and reduce intestinal inflammation has upstream CNS effects, potentially explaining some of its mood-stabilizing properties.

HPA axis normalization: BPC-157 appears to reduce excessive HPA axis reactivity, dampening cortisol responses to stressors.

GABA system interaction: Some research suggests BPC-157 interacts with GABAergic pathways, which may contribute to its anxiolytic effects.

Research Evidence

Multiple animal studies show BPC-157 reduces anxiety behaviors in the elevated plus-maze and open-field test. It has also been shown to reduce alcohol withdrawal-induced anxiety and anxiety triggered by opioid withdrawal — suggesting interaction with stress-related neurotransmitter systems. See also the peptides for gut healing guide for its GI-anxiety connection.

Dosing

250–500 mcg subcutaneously or orally (oral works well for gut-brain axis effects), once or twice daily.

Thymosin Alpha-1: Neuroinflammation and Immune-Driven Anxiety

Thymosin alpha-1 deserves mention in the anxiety context because of the increasingly recognized link between immune dysregulation, neuroinflammation, and anxiety disorders.

Elevated inflammatory cytokines (TNF-alpha, IL-6, IL-1) are consistently found in people with anxiety disorders and depression. These cytokines directly affect serotonin metabolism, HPA axis reactivity, and neural circuitry involved in threat detection. Thymosin alpha-1's ability to modulate the immune response and reduce excessive inflammatory signaling may address this pathway.

This is particularly relevant for people with anxiety following viral infections (including post-COVID anxiety), chronic infections, or autoimmune conditions where neuroinflammation is a plausible driver.

Dosing

1.6 mg subcutaneously, twice weekly. 4–8 week cycles.

A Practical Protocol for Anxiety

For most people, the starting point should be selank: it has the best evidence-to-risk ratio for anxiety specifically, with demonstrated efficacy comparable to pharmaceuticals without the sedation or dependence concerns. Intranasal administration is simple.

If cognitive improvement alongside anxiety reduction is a goal, adding semax (typically in the morning) while using selank (afternoon/evening) creates a complementary pairing that addresses both BDNF-driven resilience and acute GABAergic calming.

DSIP adds value when sleep disruption is a significant component. BPC-157 is valuable when gut dysfunction or systemic inflammation appears to be contributing to anxiety.

For more on peptide combinations, see the best peptide stacks guide.

Frequently Asked Questions

Q: Can selank replace benzodiazepines? Selank should not be used to abruptly replace benzodiazepines in people with physical dependence — benzodiazepine withdrawal is medically serious. However, for people seeking an anxiolytic without dependence risk or cognitive impairment, selank is a compelling alternative. Tapering from benzodiazepines with medical supervision while introducing selank is a documented clinical approach in Russian psychiatry.

Q: How quickly does selank work for anxiety? Many users report acute anxiety reduction within 15–30 minutes of intranasal administration. The deeper BDNF-driven neuroplasticity effects develop over 2–4 weeks of consistent use.

Q: Is semax stimulating or calming? Semax is generally described as cognitively stimulating and mood-brightening rather than sedating. It can worsen anxiety in some people, particularly at higher doses, which is why starting low is important. Selank is the more reliably calming of the two.

Q: Can these peptides be combined with SSRIs or other medications? The combination of selank or semax with SSRIs has not been formally studied. Given their different mechanisms, the risk of dangerous interaction is considered low, but this warrants physician guidance before proceeding.

Q: Are there peptides for PTSD specifically? Selank has been studied in trauma-related anxiety with positive results. More specifically, there is emerging research on intranasal oxytocin for PTSD (oxytocin is technically a peptide hormone). BPC-157's dopaminergic effects may also help with the hypervigilance component of PTSD. This remains an active area of research.